Iovance Biotherapeutics Company
Iovance Biotherapeutics develops T-cell-based immunotherapy products for the treatment of cancer.
Technology:
CAR-T, CAR-T therapy, Cell-based gene therapy
Industry:
Public
Headquarters:
New York, New York, United States
Founded Date:
2007-01-01
Employees Number:
251-500
Funding Status:
IPO
Investors Number:
4
Total Funding:
1215400000
Estimated Revenue:
$50M to $100M
Last Funding Date:
2020-05-27
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership